中山醫學大學機構典藏 CSMUIR:Item 310902500/11777
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 17918/22933 (78%)
造访人次 : 7429828      在线人数 : 45
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/11777


    题名: Plasma homocysteine status in patients with ankylosing spondylitis
    作者: Wei, James Cheng-Chung
    Jan, Ming-Shiou
    Yu, Chen tung
    Huang, Yi-Chia
    Yang, Chi-Chiang
    Tsou, Hsi-Kai
    贡献者: 中山醫學大學
    关键词: Ankylosing spondylitis;Folic acid;Homocysteine;Vitamin
    日期: 2007
    上传时间: 2015-07-29T04:24:33Z (UTC)
    ISSN: 0770-3198
    摘要: Homocysteine (Hcy), a sulfur-containing amino acid, is eliminated through B vitamins-dependent pathways. Hyperhomocysteinemia has been found to be an independent risk factor for atherosclerotic cardiovascular, cerebrovascular, and peripheral vascular diseases. Recently, psoriasis, lupus, and rheumatoid arthritis were reported to be associated with hyperhomocysteinemia. This study was aimed to evaluate the changes of plasma Hcy level before and after sulfasalazine and MTX therapy in patients with ankylosing spondylitis (AS). One hundred and two patients with AS and ten normal controls were enrolled in the cross-sectional case-control study. Fasting plasma Hcy levels were determined by ELISA kits (IMX, Abbott). Hcy levels were compared to their Bath AS disease activity index (BASDAI) and the usage of sulfasalazine and/or MTX. Active disease was defined by BASDAI as more than 3 in a 10-cm scale with ESR >20 mm/h. For those patients with plasma Hcy >or=15 micromol/l, a perspective trial of daily supplement of vitamin B-12 0.5 mg, B-6 50 mg, and folic acid 5 mg for 2 weeks were also tested for the efficacy. Plasma Hcy level increased significantly in AS patients under sulfasalazine (10.4+/-3.8 micromol/l, p<0.05), MTX (11.9+/-4.7, p<0.05) and sulfasalazine/MTX combination treatment (11.2+/-2.6, p<0.05) compared with normal controls (8.6+/-1.2 micromol/l) and AS patients without DMARD(9.4+/- 2.6 micromol/l). No correlation between disease activity and plasma Hcy level was found. Daily supplement of vitamin B-12 0.5 mg, B-6 50 mg, and folic acid 5 mg can lower Hcy level in 2 weeks (32.3+/-24.0 vs 15.6+/-11.1 micromol/l, p=0.007). Plasma homocysteine level did significantly increase in AS patients under sulfasalazine or MTX treatment. B-vitamins should be considered as a routine supplementation for patients who underwent sulfasalazine and/or MTX treatment. Further longitudinal studies are required to confirm the conclusions.

    Plasma homocysteine status in patients with ankylosing spondylitis (PDF Download Available). Available from: http://www.researchgate.net/publication/6771373_Plasma_homocysteine_status_in_patients_with_ankylosing_spondylitis [accessed Jul 29, 2015].
    URI: https://ir.csmu.edu.tw:8080/ir/handle/310902500/11777
    http://dx.doi.org/10.1007/s10067-006-0396-x
    關聯: Clinical Rheumatology (Impact Factor: 1.77). 05/2007; 26(5):739-42.
    显示于类别:[免疫學研究所] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html期刊論文0KbHTML265检视/开启


    检视Licence

    SFX Query

    在CSMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈